IONS - Ionis Pharmaceuticals, Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $-1.24
|
Rev Est: $156.1M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$88.07
DETAILS
HIGH:
$100.00
LOW:
$65.00
MEDIAN:
$94.50
CONSENSUS:
$88.07
UPSIDE:
3.07%
Market Cap:
13.84B
Volume:
2,140,750
Avg Volume:
2,084,065
52 Week Range:
23.95-86.74
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.31
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,069
IPO Date:
1991-05-17
EPS (TTM):
-3.04
P/E Ratio:
-11.52
Revenue (TTM):
705.14M
Total Assets:
3.00B
Total Debt:
1.42B
Cash & Equiv:
242.08M
Rev Growth (5Y):
-8.9%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-13.9%
Debt/Equity:
2.41
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-10-29 | $-0.61 | $-1.15 | +47.0% | $156.7M | $153.6M | +2.1% |
| 2025-07-30 | $0.68 | — | — | $452.0M | — | — |
| 2025-04-30 | $-0.75 | $-1.11 | +32.4% | $131.6M | $150.6M | -12.6% |
| 2025-02-19 | $-0.66 | $-1.09 | +39.4% | $226.6M | $131.1M | +72.8% |
| 2024-11-06 | $-0.95 | $-1.16 | +18.1% | $133.8M | $144.4M | -7.4% |
| 2024-08-01 | $-0.45 | $-0.92 | +51.1% | $225.2M | $150.1M | +50.1% |
| 2024-02-21 | $-0.06 | $-0.83 | +92.8% | $324.5M | $174.8M | +85.7% |
| 2024-01-10 | $-0.06 | $-0.83 | +92.8% | $119.5M | — | — |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 705.14M | 787.65M | 587.37M | 810.46M | 729.26M | 1.12B | 599.67M | 514.18M | 372.78M | 283.70M | 214.16M | 147.28M |
| Net Income | (453.90M) | (366.29M) | (269.72M) | (28.60M) | (444.26M) | 278.14M | 273.74M | 346,000 | (60.40M) | (88.28M) | (38.98M) | (60.64M) |
| EPS | -3.04 | -2.56 | -1.90 | -0.20 | -3.18 | 2.10 | 2.07 | -0.05 | -0.72 | -0.74 | -0.33 | -0.55 |
| Total Assets | 3.00B | 2.99B | 2.53B | 2.61B | 2.39B | 3.23B | 2.67B | 1.32B | 912.47M | 947.90M | 955.81M | 847.16M |
| Total Debt | 1.42B | 1.45B | 1.37B | 1.25B | 908.93M | 771.98M | 641.81M | 594.50M | 574.05M | 470.62M | 450.11M | 226.03M |
| Cash & Equivalents | 242.08M | 399.27M | 276.47M | 869.19M | 397.66M | 683.29M | 278.82M | 129.63M | 84.69M | 128.80M | 143.00M | 159.97M |
| Operating Cash Flow | (500.95M) | (307.51M) | (274.37M) | 30.80M | 35.89M | 345.72M | 602.89M | 174.15M | (112.11M) | 21.12M | 6.29M | 63.49M |
| Free Cash Flow | (546.23M) | (335.52M) | (294.47M) | 12.90M | (5.16M) | 309.44M | 585.24M | 136.29M | (123.63M) | 9.38M | (4.82M) | 58.13M |
| FCF per Share | -3.65 | -2.35 | -2.08 | 0.09 | -0.04 | 2.21 | 4.42 | 1.10 | -1.02 | 0.08 | -0.04 | 0.53 |
| Book Value | 588.35M | 386.69M | 572.89M | 771.74M | 743.28M | 1.47B | 1.05B | 281.01M | 99.56M | 200.79M | 257.78M | 378.39M |
| Cash & ST Investments | 2.30B | 2.33B | 2.00B | 2.13B | 1.89B | 2.50B | 2.08B | 1.02B | 665.22M | 803.98M | 810.71M | 708.86M |
| ROC Equity | -0.77 | -0.95 | -0.47 | -0.04 | -0.60 | 0.19 | 0.26 | 0.00 | -0.61 | -0.44 | -0.15 | -0.16 |